106610-41-7

Upstream product

• 6068-28-6 tosylate de n-hexadecyle 
• 54494-87-0 resorcinol; sodium-compound 
• 112-82-3 hexadecanyl bromide 
• 108-46-3 recorcinol 

Downstream Products

• 140468-10-6 4-(3-Hexadecyloxy-phenoxymethyl)-2,2-dimethyl-[1,3]dioxolane 
• 1417647-74-5 4,5-bis(3-hexadecyloxyphenoxy)-1,2-dicyanobenzene 
• 130442-04-5 3-(bromomethyl)phenyl 3-(hexadecyloxy)phenyl phosphate 
• 140467-61-4 1-(3-Hexadecyloxy-phenoxy)-3-[(4-methoxy-phenyl)-diphenyl-methoxy]-propan-2-ol 
• 140467-96-5 Phosphoric acid 3-bromomethyl-phenyl ester 3-(3-hexadecyloxy-phenoxy)-2-methoxy-propyl ester 
• 140467-76-1 3-(3-Hexadecyloxy-phenoxy)-2-methoxy-propan-1-ol 
• 140468-19-5 3-(3-Hexadecyloxy-phenoxy)-propane-1,2-diol 
• 1331960-73-6 C₆₁H₁₀₇NO₅ 
• 1331961-31-9 C₂₂H₃₇NO₄ 
• 1331960-68-9 2-hydroxy-4-hexadecyloxy-N-(2-hydroxy-4-hexadecyloxybenzylidene)aniline 
• 1331960-60-1 2,3-dihexadecyloxy-6-(6-hexadecyloxybenzooxazol-2-yl)phenol 
• 1331960-55-4 5-hexadecyloxy-2-(6-hexadecyloxybenzoxazol-2-yl)phenol 

Relevant academic research and scientific papers

2-(Dialkylamino)-4H-1-benzopyran-4-one derivatives modify chloride conductance in CFTR expressing cells

Some 2-(diethylamino)-7-hydroxy-4H-1-benzopyran-4-one derivatives, potentially useful as activators of the cystic fibrosis transmembrane conductance regulator (CFTR), were prepared. The synthesized compounds were tested, together with others 2-(dialkylami

Polarization effect in luminescent mesogenic BF2 complexes derived from heterocyclic benzothiazoles

Two series of benzo(thia)xazoles 1–2 and one series of boron difluoride complexes 2-BF2 derived from benzothiazoles 2 were reported, and their mesomorphic and optical properties were investigated. The crystal and molecular structures of compound 2 and 2-BF2 (all n = 8) were determined by means of X?ray structural analysis, and both crystallize in the triclinic P-1 and monoclinic P21/c. The geometry at boron center is perfectly tetrahedral, and the overall molecular shapes are considered as rod?shape. Both benzo(thia)xazoles 1 and 2 exhibited N or/and SmC phase, and boron complexes 2-BF2 formed N or/and SmC phase. Benzothiazoles 2 showed a much wider temperature range of mesophase than those of benzoxazoles 1, which were attributed to the better polarization by sulfur atom incorporated. Boron complexes 2-BF2 (n = 10, 12) emitted a yellow?to?green emission at λmax = 569–571 nm in CH2Cl2. This is the first mesogenic BF2 complexes derived from benzothiazoles.

Discotic liquid crystals of transition metal complexes 56 ?: Synthesis of mesogenic phthalocyanine-fullerene dyads and influence of the substitution position of alkoxy chains and the kind of terminal groups on appearance of the helical supramolecular stru

We have synthesized twelve novel discotic columnar liquid crystals based on a phenoxy-group-substituted phthalocyaninato copper(II) complex having the same alkoxy chain of C16H33O at different positions in the phenoxy group: The parent compounds {0a~0c-16

Mesogenic heterocycles derived from quinoxaline Schiff Bases

Three new series of heterocyclic quinoxaline Schiff Bases 1–2 were prepared, characterized and their mesomorphic properties were investigated. These compounds 1 and 2 are in fact geometric isomers in which an imine moiety (e.g., [sbnd]C[dbnd]N) is inversely incorporated into quinoxaline, leading to an opposite local dipole. Two single crystallographic structures 1 (m=8, n=8) and 2a (m=12, n=8) were determined by X-ray crystallographic analysis in order to understand the effect of mesomorphic properties. Weak H-bonds, CH–π and π–π interactions were found in both crystals, which were attributed to the formation of mesomorphic behavior. Variable temperature FT-IR experiments were performed to confirm the induced H-bonds. All series?of compounds 1–2 exhibited N/SmC or SmC phases, which were identified by optical microscope and confirmed by powder X-ray diffraction experiments. Compounds 2a have a slightly wider range of mesophase temperatures than that of compounds 1 and 2b.

Catenar bimetallomesogens derived from quinoxaline-salicylaldimine conjugates

The preparation, characterization, and mesomorphic properties of two series of tridentate N-salicylidene-2-hydroxyanilines and their metal complexes were described. The crystal and molecular structure of bis[2-hydroxy-4-propyloxy-N- (2-hydroxy-3,4-dipropy

Discotic liquid crystals of transition metal complexes 45?: Parity effect of the number of d-electrons on stacking distances in the columnar mesophases of octakis-(M-alkoxyphenoxy)phthalocyaninato metal(II) complexes

We have synthesized 34 novel homologous discotic liquid crystals, octakis(m-alkoxyphenoxy)phthalocyaninato metal(II) {abbreviated as (m-C nOPhO)8PcM (M = Co(1), Ni(2), Cu(3), Zn(4) and H 2(5); n = 8(a), 10(b), 12(c), 14(d)

Columnar/smectic metallomesogens derived from heterocyclic benzoxazoles

The synthesis, mesomorphic behavior, and optical properties of two new series of metal complexes 1a,b-M (M=Pd, Cu, Zn) derived from benzoxazoles 2a,b are reported. The crystal and molecular structures of mesogenic 5-decyloxy-2-(6-decyloxybenzooxazol-2-yl)

Analogues of Platelet Activating Factor. 6. Mono- and Bis-Aryl Phosphate Antagonists of Platelet Activating Factor

A series of aryl phosphoglyceride (3, 19-61) and bis-aryl phosphate (67-135) antagonists of platelet activating factor (PAF) were prepared.A group of four bifunctional phosphorus reagents (5a-c and 7) were developed that allowed the preparation of these aryl phosphates in which the position of aromatic substitution can be varied.These compounds were examined for their ability to inhibit PAF-induced platelet aggregation of rabbit platelets.Selected compounds were also evaluated for their ability to displace PAF from its receptor on rabbit platelets.These in vitro data were compared to similar data obtained for a number of known PAF antagonists.The compounds were evaluated in vivo, in both the mouse and rabbit, for their ability to prevent death induced by a lethal challenge of PAF.The relationships between the biological activity and the nature, lipophilicity, and position of substituents of the aromatic rings were studied.Compound 105 (CL 184005) has been selected to undergo further development as a potential therapeutic agent for the treatment of septic shock in man.

Bis-arylphosphate ester antagonists of platelet activating factor

The invention is novel compounds of the formula: STR1 which are antagonists of platelet activating factor.